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Background: The reward deﬁciency syndrome hypothesis posits that genes are responsible for reward dependence
and related behaviors. There is evidence that both bulimia and anorexia nervosa, especially in women, have been
linked to a lifetime history of substance use disorder (SUD). There are difﬁculties in accepting food as an addiction
similar to drugs; however, increasingly neuroimaging studies favor such an assertion. Case presentations: We are
reporting the evidence of comorbidity of eating disorders with SUD found within these case presentations. We show
50 case reports derived from two independent treatment centers in Florida that suggest the commonality between food
and drug addictions. In an attempt to provide data from this cohort, many participants did not adequately respond to
our questionnaire. Discussion: We propose that dopamine agonist therapy may be of common beneﬁt. Failure in the
past may reside in too powerful D2 agonist activity leading to D2 receptor downregulation, while the new
methodology may cause a reduction of “dopamine resistance” by inducing “dopamine homeostasis.” While this
is not a deﬁnitive study, it does provide some additional clinical evidence that these two addictions are not mutually
exclusive. Conclusion: Certainly, it is our position that there is an overlap between food- and drug-seeking behavior.
We propose that the studies focused on an effort to produce natural activation of dopaminergic reward circuitry as a
type of common therapy may certainly be reasonable. Additional research is warranted.
Keywords: food and drug addictions, commonality, dopamine pathways, reward deﬁciency syndrome, eating disorder
INTRODUCTION
The concept that food and drugs have common neurobio-
logical and neurogenetic mechanisms has been pioneered
ﬁrst by Hoebel (1985) over 25 years ago and introduced
into the media and mainstream America by Gold and Avena
(2013) and Avena’s group (Murray, Tulloch, Chen, &
Avena, 2015).
Research has revealed that obesity results in changes in
both behaviors and brain structures quite similar to the
changes observed in drug addiction. However, addiction to
food is not the cause of all cases of obesity. Can it be
assumed that a large group of individuals no longer eat to
survive, but rather survive to eat? This article considers the
importance of the brain’s reward system in food intake the
“thrifty gene hypothesis” (survival gene related to famine
and fat metabolism) and as such the commonality between
food and drug addictions (Prentice, Hennig, & Fulford,
2008; Speakman, 2006).
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Certain overlaps in the brain circuitry activation by food
and drug intake suggest that different types of reinforces
(natural and artiﬁcial) activate a number of the same
neural systems (Hernandez & Hoebel, 1990; Hoebel, 1985;
Kelley et al., 2002; Le Magnen, 1988; Volkow & Wise,
2005; Wise, Fotuhi, & Colle, 1989). In fact, there are several
regions of the brain involved in the reinforcement of both
feeding and drug intake (Baldo, Pratt, & Kelley, 2010;
Kalivas & Volkow, 2005; Koob & Le Moal, 2005;
Mogenson & Yang, 1991), and a number of neurotransmit-
ters, as well as hormones, have been studied in these related
brain areas (Baldo et al., 2010; Schoffelmeer, Wardeh, &
Vanderschuren, 2001; Simpson et al., 2012; Spangler et al.,
2004; Stein & Belluzzi, 1979).
An objective of this article is to support these
commonality theories, as proposed by Avena, Murray,
and Gold (2013) and Blum et al. (1996). In clinical
situations, treatment of both food and drug addictions
typically appears to present with reciprocal comorbidity
and this common comorbidity deserves intensive
investigation.
This pilot data from patients attending an outpatient
eating disorder program may offer an opportunity for ex-
ploration of both inheritable traits and the environmental,
genetic expression involved in eating disorders and comor-
bid drug addiction. Here, we present 50 cases of patients




Procedure. Observational data from case histories from 50
subjects attending an eating disorder program at “A new
Beginning PA,” North Miami Beach, FL, and Ocean Breeze
Recovery Program, Pompano Beach, FL, have been
investigated.
Each patient was interviewed by a clinician using a
number of intake instruments including DSM-5 criteria and
a structured interview, with duration of at least 1 hr. Each
patient was asked for their demographics, their name, age,
the location of residence, marital status (single, divorced,
married, widowed, in a relationship, or living with a part-
ner), their ethnicity, and their religion to be recorded. A
detailed assessment for eating disorder and substance abuse
history was made. The eating disorder assessment included
the onset of the eating disorder (childhood or adult) and
classiﬁcation/diagnosis of the eating disorder: Compulsive
eating (binge eating or grazing), night eating, and bulimia-
purging (i.e., self-induced vomiting, laxative abuse, diure-
tics, overexercising, restricting, or anorexia). The duration
of symptoms, frequency of substance (food, sugar, laxa-
tives, and diuretics), and body image (experiencing body
dysmorphia) and whether they were stimulated to eat more
food after eating sugar and/or ﬂour products were assessed.
Family history of eating disorders including any relatives
who had, in the past or present, eating disorders, other
addictions, and mood disorders was noted. Their current
weight and body mass index (BMI), highest weight as an
adult if adult onset, or highest weight as a child/adolescent
and lowest weight in adulthood, and diets and methods
of weight loss or weight gain if attempting to control
weight were noted. A history of any bariatric surgeries
(gastric bypass, lap band, sleeve) and any suicidal
attempts due to weight/food issues was taken. In addition,
it is critical to note that the term “eating disorders”
included all of the categories stated above including
anorexia nervosa.
The substance abuse history had listed every category
and speciﬁc names of each drug in DSM 5. The instrument
was the same as the eating disorders/food addiction history
(including all demographics noted above). In addition, a
history of suicidal attempts with drugs was taken, and
drug overdoses (frequency and names of the drugs used
to overdose) and the number of treatment modalities
attended, completed and/or left Against Medical Advice
were recorded.
Participants. The resultant information was self-
reported with input from the treatment facility staff. All
the subjects were adults, reported ages ranged between 20
and 61 years; other demographic information is listed in
Table 1.
Ethics. The study procedures were carried out in
accordance with the Declaration of Helsinki. The Institu-
tional Review Board of the PATH Foundation NY ap-
proved this study concerning obesity research. All subjects
were informed about the study and all provided informed
consent.
Results
Within the case study group, BMI of 4 subjects was normal
(18.5–24.9), BMI of 9 subjects was overweight (25–29.9),
and BMI of 37 was obese (30 or greater).
Physical characteristics including height and weight were
used to determine the BMI. Other information including a
recent food history; drug history; surgical procedures; prior
diagnosis; family history of eating disorders; family history
of addiction to psychoactive substances, and highest and
lowest weights were recorded. The percentages of the
characteristics recorded in Table 2 are broken down in the
list as follows:
– Food history breakdown: 3 sugar (6%), 25 ﬂour/sugar
(50%), and 22 no response (44%).
Table 1. Demographics of the studied cohort
Characteristics N (%) Total N (%)
Gender 30 (60) Males 50 (100)
20 (40) Females
Race 43 (86) Caucasians 50 (100)
6 (12) African-Americans
1 (2) Hispanic




6 (12) No response
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– Drug history breakdown: 8 benzodiazepines (16%),
16 opiates meaning non-heroin opiates and opioids
(32%), 14 nicotine (28%), 5 pot meaning marijuana
(10%), 9 cocaine (18%), 7 crack meaning crack
cocaine (14%), 30 alcohol (60%), 3 crystal meth
meaning methamphetamine (6%), 4 heroin (8%),
1 hallucinogens (2%), 3 polysubstance (6%), 1 sedative
(2%), 1 hypnotics (2%), 1 mushrooms (2%), and 1
fastest (2%).
– Averages for height: Males 69.6 in. (176.7 cm),
11 values were missing and females 64.1 in. (162.8 cm),
6 values were missing.
Table 2. Results of interviews and clinical instruments for the entire studied cohort
Pt









1 36 Opiates, benzodiazepines, alcohol Yes No
2 43.4 Opiates, nicotine Yes Yes 350 (158.8)/53 200 (90.7)/27
3 27.4 Alcohol, nicotine, benzodiazepines, pot Yes Yes 210 (95.3)/30 92 (42.7)/20
4 29.1 Alcohol Yes Yes 250 (113.4)/50 160 (72.6)/53
5 24.8 Alcohol Yes Yes 326 (147.9)/22 160 (72.6)/28
6 30.7 Alcohol, cocaine, heroin, benzodiazepines Yes Yes 230 (104)/15 132 (59.8)/15
7 38.3 Opiates Yes No 299 (135.6)/35 170 (77.1)/24
8 31.7 Alcohol Yes Yes 254 (115.2)/33 145 (65.8)/34
9 39.1 Alcohol, opiates Yes Yes 300 (136)/32 165 (74.8)/33
10 32.3 Opiates NR NR
11 36.3 Polysubstance NR NR
12 31.3 Cocaine NR NR
13 29.8 Sedative hypnotics NR NR
14 27 Alcohol NR NR
15 29.9 Alcohol NR NR
16 34.4 Alcohol NR NR
17 29.1 Alcohol NR NR
18 32.8 Polysubstance NR NR
19 31.1 Alcohol NR NR
20 39.6 Alcohol NR NR
21 32.6 Cocaine NR NR
22 38.4 Opiates NR NR
23 31.4 Alcohol NR NR
24 28.1 Alcohol NR NR
25 36.5 Polysubstance NR NR
26 34.3 Opiates NR NR
27 39.1 Alcohol, benzodiazepines, nicotine, pot Yes Yes 260 (117.9)/28 113 (51.3)/19
28 30.4 Alcohol, crack, nicotine NR Yes 210 (95.3)/46 140 (63.5)/37
29 53.8 Heroin, benzodiazepines, crack, nicotine Yes Yes 290 (131.5)/20 210 (95.3)/22
30 30.9 Alcohol, cocaine, heroin, benzodiazepines,
mushrooms, nicotine
NR NR 235 (106.6)/15 168 (76.2)/18
31 32.5 Crystal meth, cocaine, alcohol, pot, nicotine Yes NR 280 (127)/32 170 (77.1)/32
32 41.5 Heroin Yes Yes 305 (138.3)/16 200 (90.7)/17
33 33 Alcohol NR NR 232 (105.2)/20 175 (79.4)/18
34 27.5 Alcohol Yes NR 303 (137.4)/49 190 (86.2)/50
35 22.8 Alcohol Yes Yes 289 (131)/40 178 (80.7)/60
36 24.8 Opiates, cocaine, nicotine Yes Yes 180 (81.6)/17 120 (54.4)/17
37 22.1 Opiates, crack Yes Yes 138 (62.6)/19 89 (40.4)/16
38 35.4 Opiates Yes NR 225 (102)/24 140 (63.5)/21
39 41.5 Alcohol, nicotine Yes NR 300 (136)/39 185 (83.9)/20
40 26 Alcohol, benzodiazepines NR NR 267 (121.1)/40 155 (70.3)/40
41 33.2 Fastest, nicotine, opiates, cocaine, crack, alcohol Yes Yes 250 (113.4)/19 189 (85.7)/17
42 38.2 Alcohol, crystal meth Yes NR 230 (104.3)/39 135 (61.2)/25
43 42.2 Nicotine, cocaine, crack alcohol Yes NR 280 (127)/34 210 (95.3)/18
44 36 Alcohol NR NR 302 (137)/39 218 (98.9)/41
45 42.7 Opiates, pot, nicotine, hallucinogens NR NR 325 (147.4)/21 230 (104.3)/17
46 32.8 Alcohol, nicotine Yes NR 215 (97.5)/45 189 (85.7)/30
47 32.7 Alcohol, opiates NR Yes 260 (117.9)/31 195 (88.5)/19
48 31.5 Benzodiazepines, opiates, nicotine, pot, cocaine, crack NR NR 235 (106.6)/22 190 (86.2)/19
49 34.7 Crystal meth, opiates NR Yes 270 (122.5)/42 190 (86.2)/22
50 50.2 Opiates, crack NR NR
Note. NR= none reported; opiates= non-heroin opiates and opioids; pot=marijuana; crack= crack cocaine.
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– Averages for weight: Males 236.4 lb (107.2 kg),
11 values were missing and females 206.2 lb
(93.5 kg), 6 values were missing.
– Prior diagnosis breakdown: 3 eating disorder NOS
(6%), 6 bulimia (12%), 6 diabetes (12%), and 35 no
response (70%).
– Average BMI: 33.9 for males and 33.7 for females (see
Table 2).
– Surgical history breakdown: 8 gastric bypass (16%),
3 lap band (6%), and 39 no response (78%). Family
history of eating disorders breakdown: 23 yes (46%)
and 27 no response (54%).
– Family drug history breakdown: 17 yes (34%), 2 no
(4%), and 31 no response (62%).
In this observational pilot study, any meaningful statis-
tical analysis of the data regarding the family history of
SUD was prevented with 62% of the current patients
who either did not want to respond or did not know their
family history of SUD; however, 17 of 24 cohort families
whose drug taking history was available and all of the
people in the eating disordered cohort had a comorbid
drug history.
DISCUSSION
We have reviewed 50 case reports that indicate an explicit
relationship between food and drug seeking. The evidence
from this pilot experiment on human subjects helps the
scientiﬁc community to question the requirement for sepa-
rate treatment methods for two distinct but frequently
coexisting abnormal seeking behaviors.
Many articles have examined research developments and
current treatments for obesity, including diet and exercise,
psychotherapy, surgical interventions, and pharmacothera-
pies (Blum et al., 2011; Michaelides, Thanos, Volkow, &
Wang, 2012; Volkow & Baler, 2015). Overeating may have
important neurochemical links to drug abuse, although, less
is known about other eating disorders like bulimia and
anorexia (Jordan et al., 2003). There is an evidence that
substance use disorder (SUD) has been linked to both
bulimia and anorexia nervosa, especially in young women
(Mann et al., 2014). Some other clinical issues merit atten-
tion and provide information that shed light on the com-
monality concept of food and drug comorbidities. For
example, after several years of effective bariatric surgeries,
which used to treat obese patients, clinicians now report that
some patients are substituting compulsive overeating with
other compulsive behaviors. These behaviors involve de-
creased dopamine (DA) type 2 receptors (DRD2) and
include alcoholism, gambling, drugs, compulsive shopping,
and exercise (Cuellar-Barboza et al., 2015; Dunn et al.,
2010). Previously, evidence from psychiatric genetic
animal and human studies associating compulsive over-
eating and other compulsive behaviors was explored to
elucidate the process of addiction transfer. Potentially
because of neurochemical similarities, overeating and
obesity may act protectively by decreasing drug reward
(Hodgkins, Frost-Pineda, & Gold, 2007). Similar to the
process of opiate withdrawal, in animal sugar addiction
withdrawal models, imbalances occur in neurotransmitters,
such as acetylcholine and DA (Avena, Potenza, & Gold,
2015; Gold & Avena, 2013). In addition, several animal
neuroimaging studies have reinforced the link between food
craving and drug craving (Avena & Bocarsly, 2012).
Common intricate molecular neurobiological mechanisms
related to both food and drug addictions
Tomasi et al. (2015) reported that in comparison to neutral
cues, food and cocaine cues increasingly engaged cerebel-
lum, orbitofrontal, inferior frontal, and premotor cortices
and insula and disengaged cuneus and default mode network
(DMN). Importantly, these functional magnetic resonance
imaging (fMRI) signals were proportional to striatal D2/D3
receptors. Surprisingly, cocaine and food cues also deacti-
vated ventral striatum and hypothalamus suggesting deﬁ-
ciency. Moreover, compared to food cues, cocaine cues
produced lower activation in insula and postcentral gyrus,
and less deactivation in hypothalamus and DMN regions. In
addition, activation in cortical regions and cerebellum in-
creased in proportion to the valence of the cues, and
activation to food cues in somatosensory and orbitofrontal
cortices also increased in proportion to body mass. As
expected, longer exposure to cocaine was associated with
lower activation to both cues in occipital cortex and cere-
bellum, which could reﬂect the decreases in D2/D3 recep-
tors associated with chronicity (Tomasi et al., 2015).
The authors suggested that these ﬁndings show that
cocaine cues activate similar, though not identical, pathways
to those activated by food cues and that striatal D2/D3
receptors modulate these responses, suggesting that chronic
cocaine exposure might inﬂuence brain sensitivity not just to
drugs but also to food cues (Tomasi et al., 2015).
The term “reward deﬁciency syndrome” (RDS) was
coined to describe the genetic determinants that predict
addiction. The predictive value of being a carrier of the
DRD2 Taq A1 allele, which may cause future RDS
behaviors, was 74% (Blum, Wood, Braverman, Chen, &
Sheridan, 1995). People with the DRD2 Taq A1 allele carry
a reduced number of D2 receptors and, therefore, have
reduced DA function. In addition, RDS is polygenetic,
which involves a cascade of reward genes. The deﬁciency
concept of DA may not be the only way to gain weight and
there is also an evidence for a DA surfeit theory (Yokum,
Gearhardt, Harris, Brownell, & Stice, 2014). However, DA
function disruptions, in particular, may predispose people to
obesity and other addictive disorders. A family history of
alcoholism is considered to be a substantial obesity risk
factor (Pach et al., 2014). Thus, we hypothesize that RDS is
the cause of replacing food addiction with other addictive
behaviors and may describe this recent phenomenon of
addiction transfer that is common following bariatric surgery.
Research into the neuroscience of glucose and cocaine
treatments have shown that treatment for both food and
psychoactive substance misuse should include DA agonist
therapy inducing dopamine release as opposed to present
antagonistic DA therapy (Adler et al., 2000).
Several molecular and metabolic processes involved in
the interaction of dopaminergic system and glucose may
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provide possible common therapeutic targets for both food
and drug addictions. They include
– in the mesolimbic structure, the enkephalinergic neu-
rons are found close to the vicinity of glucose receptors;
– highly concentrated glucose triggers the calcium
channel to activate DA P12 cell release;
– a signiﬁcant connection between blood glucose and
cerebrospinal ﬂuid levels of homovanillic acid, the DA
metabolite; and
– in pharmacological doses, the glucose analog,
2-deoxyglucose (2DG), is related to improved DA
yields and produces acute glucoprivation.
Stress-induced cocaine-seeking behavior involves the
discharge of neuropeptides corticotropin-releasing factor
(CRF) and orexin-A in the ventral tegmental area (VTA).
There is a support for pharmacologically important connec-
tions between CRF and orexin-A that are dependent on the
oligomerization of orexin OX1 receptors (OX1R) and CRF1
receptor (CRF1R). CRF1R–OX1R heteromers are like the
channels of an adverse crosstalk between orexin-A and CRF
as exhibited in rat VTA and transfected cells, where it
considerably regulates dendritic DA discharge. The cocaine
target 1 receptor (1R) also links with the CRF1R–OX1R
heteromer. Cocaine binding to the 1R–CRF1R–OX1R com-
plex supports a long-standing disturbance of the orexin-
A–CRF negative crosstalk. It is within this mechanism that
cocaine sensitizes VTA cells to the stimulatory effects of
both CRF and orexin-A, hence offering a mechanism by
which stress produces cocaine seeking (Navarro et al.,
2015). The RDS model of etiology holds very well for a
variety of chemical (drugs and food) and behavioral seeking
that can result in addiction.
Dopamine function deregulation is a signiﬁcant cause of
addictive behaviors, like drug, alcohol, and food addictions.
Dopamine and other reward neurotransmitters are also a
part of a largely dispersed neural network responsible for
regulation of eating behavior, affecting both homeostatic
and hedonic mechanisms (Berridge & Kringelbach, 2015;
Li, Zuo, Yu, Ping, & Cui, 2015). Considering this, the
dopaminergic and opioidergic mechanisms are especially
involved in palatable food modulation, and opioid antago-
nists weaken drug cravings and palatable food appetite.
Therefore, palatable food cravings could be contemplated
as a type of DA-opioid-related addiction. Though there are
at least ﬁve dopaminergic receptors, the D1 and D2 have
been most associated with reward according to the research
(Li et al., 2015).
Interestingly, McCutcheon (2015) suggested that
post-ingestive mechanisms occurring from nutrients in
the gut could impact food consumption and behavioral
conditioning. The physiological processes essential to
these mechanisms are multifaceted and are thought to
join in mesolimbic DA signaling to translate post-
ingestive sensing of nutrients that have a reinforcement
reward value.
Currently, there are three chief families of opioid
receptors (μ, κ, and δ), of which the μ-receptors are most
involved in reward. The cases that show common pheno-
type between food and drug addictions suggest a common
therapeutic target (Karlsson et al., 2015). They found that
low μ-opiate receptor availability results in increased
feeding behavior. Similarly, dopaminergic agonists reduce
appetite (Frank, 2014) while DA antagonists, especially at
D2 loci, increase ingestive behavior (Liu et al., 2012).
Have we hatched the common phenotype egg and should
we consider common treatment for these two seemingly
diverse substances?
Obese versus lean humans have less striatal D2 receptors
and show fewer striatal reactions to palatable food intake
(Stice, Yokum, Blum, & Bohon, 2010). These ﬁndings align
with the idea that those who have hypofunctioning reward
circuitry are inclined to overeat, to satisfy a reward deﬁcit.
Also, decreases in striatal response to food intake forecasts
weight gain in the future for those at genetic risk for lowered
signaling of DA-based reward circuitry, particularly in
adolescents (Stice et al., 2010). There is also an alternate
possibility that a surfeit of DA may also cause weight gain
(Stice & Yokum, 2014). However, animal studies specify
that palatable food intake causes downregulation of D2
receptors, decreased D2 sensitivity, and reduced reward
sensitivity, suggesting that overeating may denote dimin-
ished striatal responsivity. Stice and Yokum (2014) and
Stice et al. (2010) examined whether or not overeating
causes decreased striatal responsivity to palatable food
intake in humans utilizing repeated measures of fMRI.
Outcomes speciﬁed that females who gained weight during
a 6-month period showed a decline in striatal response to
palatable food ingestion compared to females who had
stable weight. Together, these results imply that low sensi-
tivity to reward heightens the risk for overeating and
additionally, overeating may diminish the responsivity of
reward circuitry in a feed-forward manner, speciﬁcally in
DRD2 A1 allele carriers (Carpenter, Wong, Li, Noble, &
Heber, 2013).
Neuroimaging studies have revealed that psychoactive
substances, palatable foods, and anticipated behaviors, such
as gambling and sex, affect brain structures that activate
reward circuitry and may not be unidirectional. Psychoac-
tive substances boost DA signaling and sensitize mesolim-
bic mechanisms that have been developed to modulate the
incentive salience of reward processing (Laricchiuta,
Musella, Rossi, & Centonze, 2014). Drugs of abuse are
willingly self-administered. Either directly or indirectly,
they heighten the dopaminergic synaptic function in the
nucleus accumbens and fuel brain reward circuitry func-
tioning (creating the “high” that drug users pursue). Though
initially thought to determine the setting of hedonic tone, the
functions of dopaminergic circuitry are now understood to
be more intricate, coding for attention, reward expectancy,
disconﬁrmation of reward expectancy, and incentive moti-
vation. Elevated stress levels, along with dopaminergic
gene polymorphisms and additional neurotransmitter ge-
netic variants, may have an aggregate effect on the sus-
ceptibility to both food and drug addictions involving
epigenetic effects (Wright et al., 2015). Recently, Badgaiyan,
Sinha, Sajjad, and Wack (2015) clearly showed that do-
paminergic tone at rest is reduced in attention-deﬁcit/
hyperactivity disorder. This work suggests that subjects
presenting with comorbid aberrant seeking behavior may
share a common rubric displaying a hypodopaminergic
trait/state.
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Food and drug comorbidities observed – 50 case series
Understanding these common intricate molecular neurobio-
logical mechanisms related to both food and drug addictions
is underscored by this 50 case series, showing that 100% of
patients attending an eating disorder clinic had previous
psychoactive substance misuse history both in the present
and in the past. However, due to unknown factors like
adoption, the information on family history needs to be
more intensely investigated in this cohort or a larger cohort
in future studies. However, showing that 48% of the patients
did have a family history of eating disorders seems impor-
tant and provides some information regarding genetic in-
heritability. Our ﬁnding of 34% having a known family
history of psychoactive substance misuse also seems to be
important in terms of psychoactive substance addiction
inheritability.
Limitations
This is a small observational pilot study with only demo-
graphic information and without meaningful statistics to
support the main theme of this article. A much larger cohort
with non-eating disorder controls must be evaluated in
future studies. Also, we did not characterize the type of
psychoactive substance misuse in terms of severity, which is
important in terms of genetic commonality (Gold & Avena,
2013; Hoebel, 1985; Tomasi et al., 2015; Volkow & Wise,
2005). We are indeed encouraged, however, since all 50
subjects who entered an eating disorder clinic had comorbid
SUD or at least aberrant seeking behavior history.
Future perspectives
This study found that subjects who entered an eating
disorder clinic had comorbid substance-use-seeking behav-
ior. Many theories supported by scientiﬁc neurochemical
and genetic studies offer sound evidence that food addiction
and psychoactive drug addiction are similar (Hadad &
Knackstedt, 2014) in spite of arguments to counter this
notion (Ziauddeen & Fletcher, 2013). Genetic and epige-
netic impairments of the brain reward circuitry, which
cause hypodopaminergic functioning, deﬁne RDS (Blum
et al., 2011). RDS involves neurotransmitter exchanges
and produces abnormal craving behaviors. Animal and
human fMRI studies reinforce the hypothesis that several
similar brain circuits are disturbed during drug addic-
tion and obesity, which involves DA-modulated reward
circuits in habitual eating (Blum, Liu, Shriner, & Gold,
2011).
Recognizing the role of DNA and polymorphic links to
brain reward circuitry has steered us to an innovative
treatment for addiction, which is important to psychiatry
in the genomics era. This approach may offer support to
those who suffer from RDS. Studies have indicated that
assessing established reward gene and polymorphism panels
permits the stratiﬁcation of genetic risk for RDS. The panel
named the “Genetic Addiction Risk Score (GARS™)” is a
diagnostic instrument for genetic predispositions to RDS.
Clinical groups using this test would have the advantage of
being able to detect from an early age of those at risk for
both food and drug addiction liabilities (Blum et al., 2012;
Gold, Blum, Oscar-Berman, & Braverman, 2014).
The current failure of DA D2 agonists in clinical use
is due to chronic downregulation of the D2 receptors’
targets. Less potent D2 agonists that may upregulate D2
receptors have had some clinical success (Burris, Fausing, &
Molinoff, 1998). Thus, approaches aimed at DA func-
tion improvements, rather than treatments that block DA
function may better treat food- and drug-seeking behavior.
The signiﬁcant role that genes play in reward dependence
and associated behaviors including food and drug addictions
is emphasized by the role of DA.
Schulte, Avena, and Gearhardt (2015) reported that
processed foods, high in fat and glucose, were most fre-
quently associated with addictive-like eating behaviors.
Moreover, processing was a large, positive predictor for
whether a food was associated with problematic, addictive-
like eating behaviors. In their model, fat and glucose were
large, positive predictors of problematic food ratings. This
underscores the need to restrict these foods during recovery
from both food and drug addictions.
CONCLUSION
Based on this, pilot case series ﬁnding focus on natural
activation of dopaminergic reward circuitry as a type of
common therapy may certainly be parsimonious (Field
et al., 2014; Holderness, Brooks-Gunn, & Warren, 1994;
Hudson, Weiss, Pope, McElroy, & Mirin, 1992; Kendler
et al., 1995). While this study may not answer the deﬁnitive
question as to the true relationship between food and drugs
of abuse, it does extend the view of a commonality rather
than non-commonality. Additional research in this regard is
warranted especially further neuroimaging studies to unrav-
el the current mysteries involved in eating disorder like
anorexia and bulimia, and any links to common mechanisms
to drug-seeking behavior.
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